中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2015年
10期
809-811
,共3页
精神分裂%利培酮%齐拉西酮%临床疗效%安全性
精神分裂%利培酮%齊拉西酮%臨床療效%安全性
정신분렬%리배동%제랍서동%림상료효%안전성
schizophrenia%risperidone%ziprasidone%clinical effects%safety
目的：评价齐拉西酮和利培酮治疗精神分裂症的临床疗效及安全性。方法将120例精神分裂症患者随机分为对照组58例和试验组62例。对照组予以利培酮起始给药剂量为0.25 mg? d-1，最大给药剂量4.0 mg? d-1，每日1次；试验组予以齐拉西酮初始剂量为40 mg? d-1开始，分2次服用，按照控制情况逐渐加量，根据患者病情和耐受情况，1周之内达到最大剂量160 mg? d-1，2组均治疗8周。比较2组的临床疗效、生活质量评分及不良反应发生率有无差别。结果对照组临床总有效率为89.66％，试验组临床总有效率为91.94％，2组比较差异无统计学意义（ P＞0.05）。治疗后，试验组健康调查简表各维度评分均显著高于对照组（P＜0.05）。试验组不良反应发生率（8.06％）显著低于对照组（20.69％，P＜0.05）。结论利培酮和齐拉西酮治疗精神分裂症的临床疗效相当，但齐拉西酮改善患者生活质量更为显著，且安全性更高。
目的：評價齊拉西酮和利培酮治療精神分裂癥的臨床療效及安全性。方法將120例精神分裂癥患者隨機分為對照組58例和試驗組62例。對照組予以利培酮起始給藥劑量為0.25 mg? d-1，最大給藥劑量4.0 mg? d-1，每日1次；試驗組予以齊拉西酮初始劑量為40 mg? d-1開始，分2次服用，按照控製情況逐漸加量，根據患者病情和耐受情況，1週之內達到最大劑量160 mg? d-1，2組均治療8週。比較2組的臨床療效、生活質量評分及不良反應髮生率有無差彆。結果對照組臨床總有效率為89.66％，試驗組臨床總有效率為91.94％，2組比較差異無統計學意義（ P＞0.05）。治療後，試驗組健康調查簡錶各維度評分均顯著高于對照組（P＜0.05）。試驗組不良反應髮生率（8.06％）顯著低于對照組（20.69％，P＜0.05）。結論利培酮和齊拉西酮治療精神分裂癥的臨床療效相噹，但齊拉西酮改善患者生活質量更為顯著，且安全性更高。
목적：평개제랍서동화리배동치료정신분렬증적림상료효급안전성。방법장120례정신분렬증환자수궤분위대조조58례화시험조62례。대조조여이리배동기시급약제량위0.25 mg? d-1，최대급약제량4.0 mg? d-1，매일1차；시험조여이제랍서동초시제량위40 mg? d-1개시，분2차복용，안조공제정황축점가량，근거환자병정화내수정황，1주지내체도최대제량160 mg? d-1，2조균치료8주。비교2조적림상료효、생활질량평분급불량반응발생솔유무차별。결과대조조림상총유효솔위89.66％，시험조림상총유효솔위91.94％，2조비교차이무통계학의의（ P＞0.05）。치료후，시험조건강조사간표각유도평분균현저고우대조조（P＜0.05）。시험조불량반응발생솔（8.06％）현저저우대조조（20.69％，P＜0.05）。결론리배동화제랍서동치료정신분렬증적림상료효상당，단제랍서동개선환자생활질량경위현저，차안전성경고。
Objective To evaluate the efficacy and safety of ziprasidone versus risperidone in the treatment of schizophrenia .Methods A total of 120 patients with schizophrenia were randomly divided into treatment group (n=62) and control group(n=58).Patients in the control group were administered risperidone 0.25 mg? d-1 initially with maximum of 4.0 mg? d-1 orally, qd. And patients in the treatment group were administered of ziprasidone 40 mg? d -1 initially with maximum of 160 mg? d-1 orally, bid.All the patients received 8 weeks treatment.After treatment, the clinical efficacy ,quality of life score and side effects were compared between the two groups.Results After treatment, the clinical efficacy were 89.66% and 91.94% in control and treatment group respectively, with no statistical difference(P>0.05).The score evalua-ted by the short from health survey ( SF-36 ) was significant higher in treatment group compared with control group ( P <0.05 ) . The side effects incidence rate were 20.69% in control group and 8.06% in treatment group, which was significantly difference ( P <0.05 ) . Conclusion The clinical efficacy was not different between ziprasidone and risperidone.But ziprasidone can improve patients′quality of life much more significantly with and less adverse events .
